Venetoclax has shown significant efficacy in both AML and ALL, while dasatinib (inhibiting BCR:: ABL1) and vinaclotide (inhibiting BCL-2) have a strong synergistic effect, which may effectively “starve” and “kill” cancer cells. Here, BCL2 is linked to acute lymphoblastic leukemia.